Eligibility Criteria
Patients were included in the study if they fulfilled all of the following eligibility criteria: (1) adult patients aged ≥18 years, but ≤ 75 years; (2) diagnosed with ACS (STEMI, NSTEMI, or UA); (3) were either statin-naïve or on a low-to-moderate intensity statin therapy prior to admission and; (4) were discharged on either atorvastatin 40mg or atorvastatin 80mg. Patients were excluded if they had one of the following: (1) a known hypersensitivity to any statin; (2) active liver disease or hepatic dysfunction defined as a level of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of > three times ULN; (3) pregnancy or breast-feeding; (4) receiving proprotein convertase subtilisin/kexin Type 9 (PCSK9) inhibitor; (5) receiving ezetimibe; (6) or already on a high-intensity statin prior to ACS diagnosis and hospitalization.